Jun 30, 2009 12:54 PM in Health & Medicine | 3 comments
Mounting cost of cancer drugs raises questions about their value
How much are cancer drugs worth that may only prolong a patient’s life by a few weeks? It’s a pressing question given the rising cost of medicines, and one that a pair of National Institutes of Health researchers is urging cancer specialists to tackle now.
NIH’s Tito Fojo, who works on experimental cancer therapies, and Christine Grady, a bioethicist, call upon oncologists and the government to figure out when a costly cancer drug is worth prescribing and when it is not, saying, “We cannot ignore the cumulative costs of the tests and treatments we recommend and prescribe.”
The pair’s recent commentary in the Journal of the National Cancer Institute takes a look at drugs like Erbitux, a supplemental drug for the treatment of non-small cell lung cancer. Erbitux costs about $80,000 for 18 weeks of treatment, they write, while only prolonging life by an average of 1.2 months. The drug also carries side effects.
So is the money spent on Erbitux worthwhile? The paper outlines potential standards for oncologists to apply in assessing the value of a drug before writing a prescription.
Fojo and Grady have company in raising the cost issue. Colorectal cancer specialist Leonard Saltz, from Memorial Sloan-Kettering Cancer Center, elaborates on the problem in a recent interview with CurrentMedicine.TV. The cost of new treatments has snuck up on practitioners but now needs to be dealt with head-on, he says.
“The problem is that none of the [new] drugs do what they set out to do, which is replace that which came before them,” Saltz explains. “They get added to the mix,” he says, and drive up costs without necessarily showing an adequate benefit.
Image courtesy of fluxfoto via iStockphoto
You Might Also Like
Discuss This Article
Subscription Center
World Changing Ideas
-
Video ContestInnovation is the key to a better future. Enter your own World Changing Ideas videos in our contest.
Most Popular Blog Posts
9,000-year-old brew hitting the shelves this summer
Manipulative meow: Cats learn to vocalize a particular sound to train their human companions
Wylie Coywolf: The coyote-wolf hybrid has made its way to the Northeast
A lizard that swims through sand
Scientists urge EPA to assess potential phthalates risks
Editor's Pick
-
Time to Ban Production of Nuclear Weapons MaterialA new global treaty that cuts off production of plutonium and highly enriched uranium for nuclear weapons could jump-start nuclear disarmament and help prevent proliferation
Health & Medicine Newsletter
Get weekly coverage delivered to your inboxVideo
Podcasts
-
60-Second Science
RSS ·
iTunes
Botoxed Face Impairs Bad Feelings
click to enable
-
60-Second Science
RSS ·
iTunes
Distracted Customers' Wait Times Fly
click to enable
Slideshows
Third-hand smoke contains carcinogens too, study says
Moving forward with electronic health records
Athlete alert: Is genetic juicing set to replace steroids?
Researchers Identify Genetic Variant Linked to Faster Biological Aging
Chemical Exposure Linked to Attention Deficit Disorder in Children



